Taysha Gene Therapies (TSHA) Tops Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Join SI Premium – FREE
Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $2.76 million.
For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADP Employment Change (Aug) 38K vs 47K Expected
- FuelCell Energy (FCEL) Misses Q3 EPS by 24c
- Paradium.AI and Elcano link platforms for programmatic ad curation
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
